Literature DB >> 3106573

Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 1-methyl-4-phenylpyridinium ion on activities of the enzymes in the electron transport system in mouse brain.

Y Mizuno, N Sone, T Saitoh.   

Abstract

The effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 1-methyl-4-phenylpyridinium ion (MPP+) on activities of enzyme complexes in the electron transport system were studied using isolated mitochondrial preparations from C57BL/6J mouse brains. Both MPTP and MPP+ dose-dependently inhibited activity of NADH-ubiquinone oxidoreductase (EC 1.6.5.3). The inhibition was reversible. Preincubation of freeze-thawed mitochondria with MPTP or MPP+ had no effect on the inhibition; however, when nonfrozen mitochondria were used, NADH-ubiquinone oxidoreductase activity was reduced to 46% of that in the nonincubated sample after a 5-min preincubation with MPTP and to 77% of that in the nonincubated sample after a 5-min preincubation with MPP+. Kinetic analyses revealed that inhibition of MPTP was noncompetitive and that of MPP+ uncompetitive with respect to NADH. On the other hand, inhibition of MPTP was uncompetitive and that of MPP+ noncompetitive with respect to ubiquinone. Succinate-ubiquinone oxidoreductase (complex II), dihydroubiquinone-cytochrome c oxidoreductase (complex III), and ferrocytochrome c-oxygen oxidoreductase (EC 1.9.3.1) activities were either slightly inhibited or not inhibited by MPTP or MPP+. The significance of these findings is discussed in relation to the mechanism of MPTP-induced neuronal degeneration.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3106573     DOI: 10.1111/j.1471-4159.1987.tb05737.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  50 in total

Review 1.  MPTP as a mitochondrial neurotoxic model of Parkinson's disease.

Authors:  Serge Przedborski; Kim Tieu; Celine Perier; Miquel Vila
Journal:  J Bioenerg Biomembr       Date:  2004-08       Impact factor: 2.945

Review 2.  L-DOPA treatment from the viewpoint of neuroprotection. Possible mechanism of specific and progressive dopaminergic neuronal death in Parkinson's disease.

Authors:  Norio Ogawa; Masato Asanuma; Ikuko Miyazaki; Francisco J Diaz-Corrales; Ko Miyoshi
Journal:  J Neurol       Date:  2005-10       Impact factor: 4.849

Review 3.  Voluntary exercise delays progressive deterioration of markers of metabolism and behavior in a mouse model of Parkinson's disease.

Authors:  Jing-Huei Lai; Kai-Yun Chen; John Chung-Che Wu; Lars Olson; Stefan Brené; Chi-Zong Huang; Yen-Hua Chen; Shuo-Jhen Kang; Kuo-Hsing Ma; Barry J Hoffer; Tsung-Hsun Hsieh; Yung-Hsiao Chiang
Journal:  Brain Res       Date:  2019-06-18       Impact factor: 3.252

4.  Response to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) differs in mouse strains and reveals a divergence in JNK signaling and COX-2 induction prior to loss of neurons in the substantia nigra pars compacta.

Authors:  Justin D Boyd; Haeman Jang; Kennie R Shepherd; Ciaran Faherty; Sally Slack; Yun Jiao; Richard J Smeyne
Journal:  Brain Res       Date:  2007-08-09       Impact factor: 3.252

5.  MANF improves the MPP+/MPTP-induced Parkinson's disease via improvement of mitochondrial function and inhibition of oxidative stress.

Authors:  Yigang Liu; Jingxing Zhang; Ming Jiang; Qiong Cai; Jianmin Fang; Lingjing Jin
Journal:  Am J Transl Res       Date:  2018-05-15       Impact factor: 4.060

Review 6.  Modeling and imaging cardiac sympathetic neurodegeneration in Parkinson's disease.

Authors:  Valerie Joers; Marina E Emborg
Journal:  Am J Nucl Med Mol Imaging       Date:  2014-03-20

Review 7.  Mimicking Parkinson's Disease in a Dish: Merits and Pitfalls of the Most Commonly used Dopaminergic In Vitro Models.

Authors:  Fernanda Martins Lopes; Ivi Juliana Bristot; Leonardo Lisbôa da Motta; Richard B Parsons; Fabio Klamt
Journal:  Neuromolecular Med       Date:  2017-07-18       Impact factor: 3.843

8.  Gene-environment interaction models to unmask susceptibility mechanisms in Parkinson's disease.

Authors:  Vivian P Chou; Novie Ko; Theodore R Holman; Amy B Manning-Boğ
Journal:  J Vis Exp       Date:  2014-01-07       Impact factor: 1.355

Review 9.  Estrogens and Parkinson disease: novel approach for neuroprotection.

Authors:  Hideyuki Sawada; Shun Shimohama
Journal:  Endocrine       Date:  2003-06       Impact factor: 3.633

Review 10.  Parkinson's disease: Exit toxins, enter genetics.

Authors:  Marie Westerlund; Barry Hoffer; Lars Olson
Journal:  Prog Neurobiol       Date:  2009-11-17       Impact factor: 11.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.